Skip to content

AcuCort receives marketing authorization for the drug Zeqmelit by the Norwegian Medicines Agency

AcuCort AB (publ) (Spotlight Stock Market: ACUC) today announces that the Norwegian Medicines Agency, Statens legemiddelsverk, has approved the company’s first drug under the name Zeqmelit in Norway.

In the development of the drug Zeqmelit/ISICORT®, AcuCort has managed to combine the benefits of the well-proven substance dexamethasone and the patented user-friendly oral film for quick availability and relief in emergency situations such as severe and acute allergic reactions.

The drug was recently approved in Denmark under the name Zeqmelit and has previously been approved in Sweden under the brand name ISICORT®. The registration process for Finland is ongoing and intensive work is underway on registration applications for other priority markets. AcuCort’s goal is to commercialize Zeqmelit/ISICORT® globally, i.e. in the EU, the US and in selected key markets.

“We are very pleased that AcuCort has passed another important milestone as Zeqmelit is now approved in Norway. The fact that the company’s first innovative drug is approved throughout Scandinavia creates good conditions for a positive development of the company. I am optimistic about the upcoming commercialization and our continued growth journey,” says Jonas Jönmark, CEO of AcuCort.

This information is information that AcuCort AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person below, on September 27, 2022.

For more information, please contact:
Jonas Jönmark, CEO, AcuCort AB
Telephone: + 46 (0)70 365 5400

About AcuCort AB (publ)
AcuCort has developed and commercializes Zeqmelit/ISICORT®, a new fast-dissolving oral film to put on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly dosage form primarily for the treatment of severe and acute allergic reactions, croup in children and chemotherapy-induced nausea and vomiting (CINV) and for the treatment of patients with COVID-19 who need supplemental oxygen therapy. The product is approved in Sweden, Denmark, and Norway. Altogether, this strengthens the company’s assessment that the time to commercialization may be relatively short. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market in Sweden. Please visit